Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytosorbents CorpCTSO · Entity 7625 | Chief Financial Officer | August 07, 2023 | August 15, 2023 |
| Trulieve Cannabis Corp.TRUL · Entity 4418 | Chief Financial Officer | December 29, 2022 | January 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytosorbents Corp
Report date August 07, 2023 · Filed August 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 210,000 |
Reported balance
Holding disclosure · report date 2023-08-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 210,000 F1: Consists of (a) 45,000 restricted stock units ("RSUs"), which will vest 1/2 on the first anniversary of the date of grant and 1/2 on the second anniversary of the date of grant, subject to the executive officer's continued service with the Company as of the applicable vesting date, (b) 15,000 RSUs which will vest either upon a Change of Control or will cliff vest on the second anniversary of the date of grant, subject to the executive officer's continued service with the Company as of the applicable vesting date and (c) 150,000 RSUs which will vest only upon a Change in Control, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"), subject to the executive officer's continued service with the Company as of the applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.48 · Expires 2033-07-10 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-08-07 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: These stock options ("Annual ISOs") were granted pursuant to the Plan and will vest in accordance with the following schedule, in each case, subject to the executive officer's continued service with the Company as of the applicable vesting date: 25,000 Annual ISOs upon the six-month anniversary of the date of grant and 15,000 Annual ISOs upon each of the first, second and third anniversaries of the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.48 · Expires 2033-07-10 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2023-08-07 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: These stock options ("Performance ISOs") were granted pursuant to the Plan and will vest only upon the achievement of certain milestones pursuant to the terms of the Company's existing 2022-2025 performance pool in place for the Company's management team, subject to the executive officer's continued service with the Company as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of (a) 45,000 restricted stock units ("RSUs"), which will vest 1/2 on the first anniversary of the date of grant and 1/2 on the second anniversary of the date of grant, subject to the executive officer's continued service with the Company as of the applicable vesting date, (b) 15,000 RSUs which will vest either upon a Change of Control or will cliff vest on the second anniversary of the date of grant, subject to the executive officer's continued service with the Company as of the applicable vesting date and (c) 150,000 RSUs which will vest only upon a Change in Control, as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"), subject to the executive officer's continued service with the Company as of the applicable vesting date.
F2: These stock options ("Annual ISOs") were granted pursuant to the Plan and will vest in accordance with the following schedule, in each case, subject to the executive officer's continued service with the Company as of the applicable vesting date: 25,000 Annual ISOs upon the six-month anniversary of the date of grant and 15,000 Annual ISOs upon each of the first, second and third anniversaries of the date of grant.
F3: These stock options ("Performance ISOs") were granted pursuant to the Plan and will vest only upon the achievement of certain milestones pursuant to the terms of the Company's existing 2022-2025 performance pool in place for the Company's management team, subject to the executive officer's continued service with the Company as of the applicable vesting date.
Trulieve Cannabis Corp.
Report date December 29, 2022 · Filed January 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Subordinate Voting SharesSEC Table I · non-derivative | Direct | 82,869 |
Reported balance
After 2022-12-29 transaction · row 1
1 source rowRow 1 · 2022-12-29 · Tax withholding · Disposed 2,718 · Balance 82,869 F1: Represents shares withheld for payment of tax liability in connection with vesting of 50% of restricted stock units ("RSUs") granted to the reporting person on September 29, 2021 and previously reported on Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld for payment of tax liability in connection with vesting of 50% of restricted stock units ("RSUs") granted to the reporting person on September 29, 2021 and previously reported on Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 29, 2022 Filed Jan 3, 2023 17:29 UTC | Trulieve Cannabis Corp. TRUL · Entity 4418 | Tax withholdingSubordinate Voting Shares | 2,718 | $7.74 | $21,037.32 |
DisclosureSEC source: 0001209191-23-000333 · doc4.xml · nonDerivative · entry 1 D'Amico Alex · CIK 0001419928 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,869 F1 · shares: Represents shares withheld for payment of tax liability in connection with vesting of 50% of restricted stock units ("RSUs") granted to the reporting person on September 29, 2021 and previously reported on Form 4. Read SEC document |
| May 24, 2022 Filed May 25, 2022 20:28 UTC | Trulieve Cannabis Corp. TRUL · Entity 4418 | PurchaseSubordinate Voting Shares | 1,500 | $14.39 | $21,585.00 |
DisclosureSEC source: 0001209191-22-032010 · doc4.xml · nonDerivative · entry 1 D'Amico Alex · CIK 0001419928 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,587 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.36 to $14.40, inclusive. The reporting person undertakes to provide Trulieve Cannabis Corp., any security holder of Trulieve Cannabis Corp. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 20:52 UTC | Trulieve Cannabis Corp. TRUL · Entity 4418 | GrantStock Option (Right to Buy) · Derivative | 57,343 | $0.00 Strike: $21.48 | $0.00 |
DisclosureSEC source: 0001209191-22-013799 · doc4.xml · derivative · entry 2 D'Amico Alex · CIK 0001419928 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,343 Underlying: Subordinate Voting Shares · 57,343 shares Expires 2029-02-24 F2 · derivative.exercise_date: The option becomes exercisable in three annual installments, with one-third vesting on December 1, 2022, one-third vesting on December 1, 2023, and one-third vesting on December 1, 2024. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 20:52 UTC | Trulieve Cannabis Corp. TRUL · Entity 4418 | GrantSubordinate Voting Shares | 20,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013799 · doc4.xml · nonDerivative · entry 1 D'Amico Alex · CIK 0001419928 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,135 F1 · kind: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one Trulieve Cannabis Corp. subordinate voting share. 50% of the RSUs will vest on December 1, 2023, and the remaining 50% of the RSUs will vest on December 1, 2024. Read SEC document |
| September 29, 2021 Filed Sep 30, 2021 16:31 UTC | Trulieve Cannabis Corp. TRUL · Entity 4418 | GrantStock Option (Right to Buy) · Derivative | 53,433 | $0.00 Strike: $26.88 | $0.00 |
DisclosureSEC source: 0001754195-21-000051 · edgar.xml · derivative · entry 2 D'Amico Alex · CIK 0001419928 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,433 Underlying: Subordinate Voting Shares · 53,433 shares Expires 2031-09-29 F2 · derivative.exercise_date: The option becomes exercisable in three annual installments, with one-third vesting on December 1, 2021, one-third vesting on December 1, 2022 and one-third vesting on December 1, 2023. Read SEC document |
| September 29, 2021 Filed Sep 30, 2021 16:31 UTC | Trulieve Cannabis Corp. TRUL · Entity 4418 | GrantSubordinate Voting Shares | 16,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001754195-21-000051 · edgar.xml · nonDerivative · entry 1 D'Amico Alex · CIK 0001419928 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,910 F1 · kind: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one Trulieve Cannabis Corp. subordinate voting share. 50% of the RSUs will vest on December 1, 2022 and the remaining 50% of the RSUs will vest on December 1, 2023. Read SEC document |
| September 29, 2021 Filed Oct 28, 2021 20:28 UTC Amendment | Trulieve Cannabis Corp. TRUL · Entity 4418 | GrantStock Option (Right to Buy) · Derivative | 53,433 | $0.00 Strike: $26.88 | $0.00 |
DisclosureSEC source: 0001754195-21-000076 · edgar.xml · derivative · entry 1 D'Amico Alex · CIK 0001419928 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,433 Underlying: Subordinate Voting Shares · 53,433 shares Expires 2028-09-29 F1 · derivative.exercise_date: The option becomes exercisable in three annual installments, with one-third vesting on December 1, 2021, one-third vesting on December 1, 2022 and one-third vesting on December 1, 2023. F2 · derivative.expiration_date: The original Form 4 filed on September 30, 2021 is amended by this Form 4 amendment to correct the expiration date, which was incorrectly reported in the original filing due to a clerical error. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 17:05 UTC | Trulieve Cannabis Corp. TRUL · Entity 4418 | PurchaseSubordinate Voting Shares | 660 | $27.00 | $17,820.00 |
DisclosureSEC source: 0001754195-21-000041 · edgar.xml · nonDerivative · entry 1 D'Amico Alex · CIK 0001419928 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,820 Read SEC document |
| May 28, 2021 Filed May 28, 2021 19:15 UTC | Trulieve Cannabis Corp. TRUL · Entity 4418 | PurchaseSubordinate Voting Shares | 660 | $38.00 | $25,077.36 |
DisclosureSEC source: 0001754195-21-000034 · edgar.xml · nonDerivative · entry 1 D'Amico Alex · CIK 0001419928 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,160 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.